Deepak Jain - ProKidney Corp Chief Officer
| PROK Stock | USD 1.85 0.03 1.60% |
Insider
Deepak Jain is Chief Officer of ProKidney Corp
| Age | 70 |
| Address | 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103 |
| Phone | 336 999 7028 |
| Web | https://www.prokidney.com |
ProKidney Corp Management Efficiency
The company has return on total asset (ROA) of (0.2037) % which means that it has lost $0.2037 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3134) %, meaning that it created substantial loss on money invested by shareholders. ProKidney Corp's management efficiency ratios could be used to measure how well ProKidney Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.03 this year, although the value of Return On Tangible Assets will most likely fall to (0.09). Total Current Liabilities is expected to rise to about 26.3 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 223.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Margaret JD | Revolution Medicines | 61 | |
| Brian MBA | Immunocore Holdings | 57 | |
| Mark Murcko | Relay Therapeutics | 64 | |
| Troy JD | Kura Oncology | 55 | |
| Edward MD | Third Harmonic Bio | 51 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Debra Nielsen | Immunocore Holdings | N/A | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Hal MD | Pliant Therapeutics | N/A | |
| Esq JD | Kura Oncology | 58 | |
| Thomas Catinazzo | Relay Therapeutics | 47 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Cecilia Geuijen | Merus BV | N/A | |
| Natalie Holles | Third Harmonic Bio | 51 | |
| MBA MD | Pliant Therapeutics | 56 | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Wei MD | Erasca Inc | 54 | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Elizabeth Homans | Lyell Immunopharma | 58 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 |
ProKidney Corp Leadership Team
Elected by the shareholders, the ProKidney Corp's board of directors comprises two types of representatives: ProKidney Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProKidney. The board's role is to monitor ProKidney Corp's management team and ensure that shareholders' interests are well served. ProKidney Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProKidney Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MD, VP Devel | ||
| Ashley Johns, VP Operations | ||
| Carla Poulson, Chief Officer | ||
| James CPA, Chief Officer | ||
| Richard Williams, Senior Technology | ||
| Aparna MD, VP Development | ||
| Kerry MD, VP Affairs | ||
| Bruce MD, CEO Director | ||
| Mary Weger, Chief Officer | ||
| Esq JD, Chief Sec | ||
| Darin Weber, VP Devel | ||
| Deepak Jain, Chief Officer | ||
| Dr DVM, Founder Advisor | ||
| Emily Butler, Senior Biometric | ||
| Nikhil PereiraKamath, Chief Officer | ||
| Pharm MPH, Senior Relations | ||
| Libbie MD, Chief Officer | ||
| MPH MD, Senior Procedures |
ProKidney Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProKidney Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (163.63 M) | ||||
| Shares Outstanding | 127.97 M | ||||
| Shares Owned By Insiders | 27.43 % | ||||
| Shares Owned By Institutions | 43.58 % | ||||
| Number Of Shares Shorted | 10.7 M | ||||
| Price To Book | 91.32 X | ||||
| EBITDA | (147.67 M) | ||||
| Net Income | (135.45 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.